China's Tasly Biopharma turns a development partner into an investor as it preps Hong Kong IPO
In a major endorsement of their Chinese partner’s drug development prowess, France’s Transgene is swapping ownership of a joint venture — and control of their assets …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
